Targeting STAT3 Enzyme for Cancer Treatment

Overview

Journal Mini Rev Med Chem

Publisher Bentham Science Publishers

Specialty Chemistry

Date 2024 Feb 1

PMID 38299278

Authors

Sowmiya Arun

Praveen Kumar Patel

Kaviarasan Lakshmanan

Kalirajan Rajangopal

Gomathi Swaminathan

Gowramma Byran

Affiliations

Soon will be listed here.

Abstract

A category of cytoplasmic transcription factors called STATs mediates intracellular signaling, which is frequently generated at receptors on cell surfaces and subsequently sent to the nucleus. STAT3 is a member of a responsible for a variety of human tumor forms, including lymphomas, hematological malignancies, leukemias, multiple myeloma and several solid tumor types. Numerous investigations have demonstrated constitutive STAT3 activation lead to cancer development such as breast, head and neck, lung, colorectal, ovarian, gastric, hepatocellular, and prostate cancers. It's possible to get a hold of the book here. Tumor cells undergo apoptosis when STAT3 activation is suppressed. This review highlights the STAT3 activation and inhibition which can be used for further studies.

References

Zou S, Tong Q, Liu B, Huang W, Tian Y, Fu X . Targeting STAT3 in Cancer Immunotherapy. Mol Cancer. 2020; 19(1):145. PMC: 7513516. DOI: 10.1186/s12943-020-01258-7. View

Bournazou E, Bromberg J . Targeting the tumor microenvironment: JAK-STAT3 signaling. JAKSTAT. 2013; 2(2):e23828. PMC: 3710325. DOI: 10.4161/jkst.23828. View

Christofi T, Baritaki S, Falzone L, Libra M, Zaravinos A . Current Perspectives in Cancer Immunotherapy. Cancers (Basel). 2019; 11(10). PMC: 6826426. DOI: 10.3390/cancers11101472. View

Lin W, Chang Y, Hong M, Hsu T, Lee K, Lin C . STAT3 phosphorylation at Ser727 and Tyr705 differentially regulates the EMT-MET switch and cancer metastasis. Oncogene. 2020; 40(4):791-805. PMC: 7843420. DOI: 10.1038/s41388-020-01566-8. View

Ishibashi K, Koguchi T, Matsuoka K, Onagi A, Tanji R, Takinami-Honda R . Interleukin-6 induces drug resistance in renal cell carcinoma. Fukushima J Med Sci. 2018; 64(3):103-110. PMC: 6305783. DOI: 10.5387/fms.2018-15. View

Priego N, Zhu L, Monteiro C, Mulders M, Wasilewski D, Bindeman W . STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. Nat Med. 2018; 24(7):1024-1035. DOI: 10.1038/s41591-018-0044-4. View

Resemann H, Watson C, Lloyd-Lewis B . The Stat3 paradox: a killer and an oncogene. Mol Cell Endocrinol. 2013; 382(1):603-611. DOI: 10.1016/j.mce.2013.06.029. View

Wang T, Fahrmann J, Lee H, Li Y, Tripathi S, Yue C . JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. Cell Metab. 2017; 27(1):136-150.e5. PMC: 5777338. DOI: 10.1016/j.cmet.2017.11.001. View

Morris R, Kershaw N, Babon J . The molecular details of cytokine signaling via the JAK/STAT pathway. Protein Sci. 2018; 27(12):1984-2009. PMC: 6237706. DOI: 10.1002/pro.3519. View

10.

Lee H, Pal S, Reckamp K, Figlin R, Yu H . STAT3: a target to enhance antitumor immune response. Curr Top Microbiol Immunol. 2010; 344:41-59. PMC: 3244828. DOI: 10.1007/82_2010_51. View

11.

Fathi N, Rashidi G, Khodadadi A, Shahi S, Sharifi S . STAT3 and apoptosis challenges in cancer. Int J Biol Macromol. 2018; 117:993-1001. DOI: 10.1016/j.ijbiomac.2018.05.121. View

12.

Perez C, Mondejar R, Garcia-Diaz N, Cereceda L, Leon A, Montes S . Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-κB and nuclear factor of activated T cells pathways. Br J Dermatol. 2019; 182(1):147-155. DOI: 10.1111/bjd.18098. View

13.

Zamaraev A, Kopeina G, Zhivotovsky B, Lavrik I . Cell death controlling complexes and their potential therapeutic role. Cell Mol Life Sci. 2014; 72(3):505-517. PMC: 11113151. DOI: 10.1007/s00018-014-1757-2. View

14.

Pistritto G, Trisciuoglio D, Ceci C, Garufi A, DOrazi G . Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging (Albany NY). 2016; 8(4):603-19. PMC: 4925817. DOI: 10.18632/aging.100934. View

15.

Indran I, Tufo G, Pervaiz S, Brenner C . Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. Biochim Biophys Acta. 2011; 1807(6):735-45. DOI: 10.1016/j.bbabio.2011.03.010. View

16.

Rozovski U, Calin G, Setoyama T, DAbundo L, Harris D, Li P . Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells. Mol Cancer. 2013; 12:50. PMC: 3671957. DOI: 10.1186/1476-4598-12-50. View

17.

Abroun S, Saki N, Ahmadvand M, Asghari F, Salari F, Rahim F . STATs: An Old Story, Yet Mesmerizing. Cell J. 2015; 17(3):395-411. PMC: 4601860. DOI: 10.22074/cellj.2015.1. View

18.

Wake M, Watson C . STAT3 the oncogene - still eluding therapy?. FEBS J. 2015; 282(14):2600-11. DOI: 10.1111/febs.13285. View

19.

Zhang H, Yang P, Li E, Xu L . STAT3beta, a distinct isoform from STAT3. Int J Biochem Cell Biol. 2019; 110:130-139. DOI: 10.1016/j.biocel.2019.02.006. View

20.

Chakraborty A, Dyer K, Cascio M, Mietzner T, Tweardy D . Identification of a novel Stat3 recruitment and activation motif within the granulocyte colony-stimulating factor receptor. Blood. 1998; 93(1):15-24. View